Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Wenzhou Medical UniversityNo recent work listed

Bingren Hu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5020514321. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
3
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 3

  1. Berbamine Exerts an Anti-oncogenic Effect on Pancreatic Cancer by Regulating Wnt and DNA Damage-related Pathways. First author DOI 10.2174/1871520622666220509174306↗
  2. Berbamine Enhances the Efficacy of Gefitinib by Suppressing STAT3 Signaling in Pancreatic Cancer Cells. Co-author DOI 10.2147/ott.s223242↗
  3. Design, synthesis, and biological evaluation of novel EF24 and EF31 analogs as potential IκB kinase β inhibitors for the treatment of pancreatic cancer. Last author DOI 10.2147/dddt.s133172↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gang Chen · 2 shared papers, 2019–2023 · strength 0.32
  2. Xinwei Chen · 1 shared paper, 2023 · strength 0.20
  3. Xuemeng Xie · 1 shared paper, 2017 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.